We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Microneedle Patch Detects Skin Cancer Early

By LabMedica International staff writers
Posted on 31 May 2024
Print article
Image: Illustration of the microneedle patch (Photo courtesy of Karolinska Institutet)
Image: Illustration of the microneedle patch (Photo courtesy of Karolinska Institutet)

Wearable bioelectronics has emerged as a significant innovation in healthcare, especially in the field of biosensing, providing a new method to monitor individual health for both diagnostic and therapeutic purposes. Despite its advancements, there has been a lack of progress specifically in the area of cancer, and more notably in skin cancer detection. Researchers have now introduced a novel technique for identifying malignant melanoma, which is the most serious type of skin cancer and also the fastest growing.

A groundbreaking study conducted by researchers at Karolinska Institutet (Stockholm, Sweden) led to the development of a new type of patch equipped with microneedles designed to detect the biomarker tyrosinase directly within the skin. Tyrosinase is an enzyme that serves as a crucial biomarker for malignant melanoma. By assessing the enzyme directly in the skin, this approach allows for the rapid detection of changes indicative of the disease. The feasibility of this transdermal microneedle sensor for directly quantifying tyrosinase has been demonstrated in an ex vivo skin model.

In their research, scientists employed human tissue samples from healthy individuals. They applied tyrosinase to these samples to simulate the presence of skin cancer. Their findings suggest that this new patch could serve as an effective alternative to traditional diagnostic techniques, facilitating earlier detection and treatment of malignant melanoma. The researchers are optimistic that their invention will reduce the need for invasive procedures and enhance the quality of life for patients. This innovation marks a significant step forward in improving skin health monitoring and could potentially be adapted to detect other biomarkers simply by altering its design.

“Our method is less invasive and has the potential to provide faster and more reliable results compared to traditional biopsies,” said Onur Parlak, Associate Professor at Karolinska Institutet. “Our goal is to continue developing and improving this technique to offer more accurate and painless diagnostics.” 

Related Links:
Karolinska Institutet


Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The blood test uses AI to predict Parkinson’s seven years before onset of symptoms (Photo courtesy of Kateryna Kon/Shutterstock)

AI-Powered Blood Test Predicts Parkinson's Seven Years before Symptoms Appear

Parkinson’s disease is currently the fastest-growing neurodegenerative disorder worldwide, affecting nearly 10 million people globally. It is a progressive disease caused by the deterioration and death... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.